PTHS · Pelthos Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| LIGAND PHARMACEUTICALS INC 10% Owner | ▼ Sell | Other | 1,500,000 Shares held | 7/1/2025 | View profile |
| Friedberg Ezra M Director | ▼ Sell | Open Market | 80,484 Shares held | 10/2/2026 | View profile |
| Davis Todd C Director | ▲ Buy | Open Market | 75,834 Shares held | 6/11/2026 | View profile |
| Malamut Richard EVP and Chief Medical Officer | ▼ Sell | Open Market | 27,422 Shares held | 4/2/2026 | View profile |
| Peter Greenleaf Director | ▼ Sell | Open Market | 23,087 Shares held | 10/2/2026 | View profile |
| Matthew Pauls Director | ▼ Sell | Open Market | 13,578 Shares held | 10/2/2026 | View profile |
| Einhorn Andrew J. Director | ▲ Buy | Grant | 12,000 Shares held | 12/23/2025 | View profile |
| Knuettel Francis II Director | ▼ Sell | Open Market | 11,316 Shares held | 5/22/2026 | View profile |
Transaction History
| Peter Greenleaf | ▼ Sell | Open Market | 797 | $17K | 10/2/2026 |
| Friedberg Ezra M | ▼ Sell | Open Market | 558 | $12K | 10/2/2026 |
| Matthew Pauls | ▼ Sell | Open Market | 786 | $17K | 10/2/2026 |
| Friedberg Ezra M | ▼ Sell | Open Market | 534 | $14K | 7/2/2026 |
| Friedberg Ezra M | ▼ Sell | Open Market | 24 | $656 | 7/2/2026 |
| Matthew Pauls | ▼ Sell | Open Market | 692 | $18K | 7/2/2026 |
| Matthew Pauls | ▼ Sell | Open Market | 94 | $3K | 7/2/2026 |
| Peter Greenleaf | ▼ Sell | Open Market | 712 | $19K | 7/2/2026 |
| Peter Greenleaf | ▼ Sell | Open Market | 85 | $2K | 7/2/2026 |
| Friedberg Ezra M | ▼ Sell | Open Market | 224 | $6K | 6/15/2026 |
| Friedberg Ezra M | ▼ Sell | Open Market | 59 | $2K | 6/15/2026 |
| Davis Todd C | ▲ Buy | Open Market | 35,445 | $986K | 6/11/2026 |
| Davis Todd C | ▲ Buy | Open Market | 503 | $14K | 6/11/2026 |
| Knuettel Francis II | ▼ Sell | Other | 13,947 | $0 | 5/22/2026 |
| Knuettel Francis II | ▼ Sell | Open Market | 1,500 | $40K | 5/22/2026 |
| Friedberg Ezra M | ▼ Sell | Tax Withholding | 144 | $4K | 5/14/2026 |
| Malamut Richard | ▼ Sell | Open Market | 310 | $6K | 4/2/2026 |
| Malamut Richard | ▼ Sell | Open Market | 280 | $6K | 4/2/2026 |
| Friedberg Ezra M | ▼ Sell | Open Market | 293 | $6K | 4/2/2026 |
| Friedberg Ezra M | ▼ Sell | Open Market | 265 | $6K | 4/2/2026 |
| Matthew Pauls | ▼ Sell | Open Market | 415 | $9K | 4/2/2026 |
| Matthew Pauls | ▼ Sell | Open Market | 371 | $8K | 4/2/2026 |
| Peter Greenleaf | ▼ Sell | Open Market | 420 | $9K | 4/2/2026 |
| Peter Greenleaf | ▼ Sell | Open Market | 377 | $8K | 4/2/2026 |
| Einhorn Andrew J. | ▲ Buy | Grant | 12,000 | — | 12/23/2025 |
| Matthew Pauls | ▼ Sell | Gift | 9,542 | $0 | 12/10/2025 |
| Friedberg Ezra M | ▼ Sell | Open Market | 5,999 | $168K | 11/25/2025 |
| Friedberg Ezra M | ▼ Sell | Open Market | 2,000 | $56K | 11/25/2025 |
| Friedberg Ezra M | ▼ Sell | Open Market | 1 | $29 | 11/25/2025 |
| Friedberg Ezra M | ▼ Sell | Open Market | 2,000 | $56K | 11/25/2025 |
| Matthew Pauls | ▲ Buy | Option Exercise | 2,123 | $0 | 10/2/2025 |
| Matthew Pauls | ▲ Buy | Option Exercise | 8,493 | $0 | 7/2/2025 |
| Knuettel Francis II | ▼ Sell | Other | 10,000 | $100K | 7/1/2025 |
| LIGAND PHARMACEUTICALS INC | ▼ Sell | Other | 1,500,000 | $15.0M | 7/1/2025 |
| Friedberg Ezra M | ▼ Sell | Other | 40,000 | $400K | 7/1/2025 |
| Friedberg Ezra M | ▼ Sell | Other | 40,000 | $400K | 7/1/2025 |
| Davis Todd C | ▼ Sell | Other | 1,500,000 | $15.0M | 7/1/2025 |
| Knuettel Francis II | ▲ Buy | Open Market | 3,500 | $3K | 9/13/2024 |
| Malamut Richard | ▲ Buy | Open Market | 10,400 | $10K | 9/12/2024 |
| Knuettel Francis II | ▲ Buy | Open Market | 1,700 | $2K | 9/12/2024 |
| Knuettel Francis II | ▲ Buy | Open Market | 5,500 | $5K | 9/11/2024 |
| Knuettel Francis II | ▲ Buy | Open Market | 6,500 | $6K | 9/10/2024 |
| Knuettel Francis II | ▼ Sell | Gift | 15,000 | $0 | 6/28/2024 |
| Knuettel Francis II | ▼ Sell | Gift | 5,000 | $0 | 6/28/2024 |
| Friedberg Ezra M | ▲ Buy | Option Exercise | 6,992 | $34K | 2/21/2024 |
| Davis Todd C | ▲ Buy | Option Exercise | 29,167 | $140K | 2/21/2024 |
| Friedberg Ezra M | ▲ Buy | Option Exercise | 13,649 | $66K | 2/21/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Pelthos Expands Coverage for ZELSUVMI Topical Gel
Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.
Pelthos Expands Coverage for ZELSUVMI Topical Gel. Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.